Insider Transactions in Q4 2022 at Vertex Pharmaceuticals Inc (VRTX)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 06
2022
|
Stuart A Arbuckle EVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
12,753
+18.02%
|
-
|
|
Nov 15
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
34
-0.09%
|
$10,472
$308.61 P/Share
|
|
Nov 07
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,303
-0.51%
|
$394,809
$303.2 P/Share
|
|
Nov 07
2022
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,303
+3.37%
|
$243,661
$187.53 P/Share
|
|
Nov 02
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
320
-0.12%
|
$100,160
$313.56 P/Share
|
|
Nov 01
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
768
-1.96%
|
$239,616
$312.84 P/Share
|
|
Oct 24
2022
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
621
-13.32%
|
$192,510
$310.0 P/Share
|
|
Oct 18
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
1,791
-2.2%
|
$537,300
$300.93 P/Share
|